Agriculture business to weigh further on 2025 earnings Bayer shares down 11.6% to two-decade low Investor urges more efforts, demands mid-term targets FRANKFURT, Nov 12 (Reuters) - Bayer (BAYGn.DE ...

Bayer BAYN2.76%increase; green up pointing triangle cut its full-year earnings target after a tough agricultural market hit its crop-science division, and said it heads into next year with a muted ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Bayer has filed for approval in the US for elinzanetant as a non-hormonal treatment for menopausal symptoms such as hot flushes, with a rival therapy from Astellas in its sights. The FDA ...

Hedge fund D.E. Shaw took a 102 million euro ($108 million) short bet against Bayer on Tuesday, a regulatory filing in Germany showed, following an earnings presentation that sent its shares to a ...

Bayer Cropscience Ltd., incorporated in the year 1958, is a Mid Cap company (having a market cap of Rs 26,483.70 Crore) operating in Pesticides/Agro Chemicals sector. Bayer Cropscience Ltd. key ...

Bayer's move leaves Merck still out in front – with an approval for gefapixant for cough in Japan where the drug is known as Lyfnua – but clearly casts a shadow on the class as a whole.